Drug intelligence / Profile preview

lepidoglyphus destructor extract

Development stage
Unknown
Lead developer
Inmunotek
Modality
Vaccines & Immunotherapeutics
Administration
Sublingual, Subcutaneous
01

Overview

Lepidoglyphus destructor extract is a biological allergen preparation developed by Inmunotek S.L. for the treatment of Type I hypersensitivity reactions to the storage mite *Lepidoglyphus destructor*. Commonly found in agricultural settings and stored food products, this mite is a significant trigger for allergic rhinitis and asthma. The extract is used in allergen immunotherapy (AIT) to desensitize patients by repeatedly exposing them to controlled doses of the allergen, thereby promoting immunological tolerance. Inmunotek provides this extract in various platforms, including the sublingual spray Oraltek and the subcutaneous alum-precipitated suspension Alunitek. The therapeutic goal is to modify the underlying allergic disease by inducing peripheral T-cell tolerance and shifting the immune response from a Th2-dominated allergic profile to a Th1/Treg-mediated profile.

Brand names
OraltekAlunitekBactek
Other names
Storage mite extractLepidoglyphus destructor allergen extract
02

Targets

A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)

Beyond the preview

Go deeper on lepidoglyphus destructor extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lepidoglyphus destructor extract.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call